Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Cooled radiofrequency ablation of the genicular nerves for chronic pain due to osteoarthritis of the knee: a cost-effectiveness analysis based on trial data.

Desai M, Bentley A, Keck WA, Haag T, Taylor RS, Dakin H.

BMC Musculoskelet Disord. 2019 Jun 26;20(1):302. doi: 10.1186/s12891-019-2681-2.

2.

Radical changes in medical education needed globally.

Ebrahim S, Squires N, di Fabio JL, Reed G, Bourne PG, Keck W, Neusy AJ, Chalkidou K.

Lancet Glob Health. 2015 Mar;3(3):e128-9. doi: 10.1016/S2214-109X(15)70013-6. No abstract available.

3.

Novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram positive activity and improved safety profile.

Surivet JP, Zumbrunn C, Rueedi G, Bur D, Bruyère T, Locher H, Ritz D, Seiler P, Kohl C, Ertel EA, Hess P, Gauvin JC, Mirre A, Kaegi V, Dos Santos M, Kraemer S, Gaertner M, Delers J, Enderlin-Paput M, Weiss M, Sube R, Hadana H, Keck W, Hubschwerlen C.

J Med Chem. 2015 Jan 22;58(2):927-42. doi: 10.1021/jm501590q. Epub 2014 Dec 23.

PMID:
25494934
4.

Ebola control: the Cuban approach.

Ebrahim S, Squires N, Díaz MB, di Fabio JL, Reed G, Bourne PG, Keck W, Chalkidou K.

Lancet. 2014 Dec 6;384(9959):2022. doi: 10.1016/S0140-6736(14)62329-1. No abstract available.

PMID:
25483161
5.

Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.

Locher HH, Caspers P, Bruyère T, Schroeder S, Pfaff P, Knezevic A, Keck W, Ritz D.

Antimicrob Agents Chemother. 2014;58(2):901-8. doi: 10.1128/AAC.01831-13. Epub 2013 Nov 25.

6.

In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.

Locher HH, Seiler P, Chen X, Schroeder S, Pfaff P, Enderlin M, Klenk A, Fournier E, Hubschwerlen C, Ritz D, Kelly CP, Keck W.

Antimicrob Agents Chemother. 2014;58(2):892-900. doi: 10.1128/AAC.01830-13. Epub 2013 Nov 25.

7.

Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity.

Surivet JP, Zumbrunn C, Rueedi G, Hubschwerlen C, Bur D, Bruyère T, Locher H, Ritz D, Keck W, Seiler P, Kohl C, Gauvin JC, Mirre A, Kaegi V, Dos Santos M, Gaertner M, Delers J, Enderlin-Paput M, Boehme M.

J Med Chem. 2013 Sep 26;56(18):7396-415. doi: 10.1021/jm400963y. Epub 2013 Sep 11.

PMID:
23968485
8.

Role of autofluorescence in flow cytometric analysis of Escherichia coli treated with bactericidal antibiotics.

Renggli S, Keck W, Jenal U, Ritz D.

J Bacteriol. 2013 Sep;195(18):4067-73. doi: 10.1128/JB.00393-13. Epub 2013 Jul 8.

9.

Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity.

Surivet JP, Lange R, Hubschwerlen C, Keck W, Specklin JL, Ritz D, Bur D, Locher H, Seiler P, Strasser DS, Prade L, Kohl C, Schmitt C, Chapoux G, Ilhan E, Ekambaram N, Athanasiou A, Knezevic A, Sabato D, Chambovey A, Gaertner M, Enderlin M, Boehme M, Sippel V, Wyss P.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6705-11. doi: 10.1016/j.bmcl.2012.08.094. Epub 2012 Sep 4.

PMID:
23006603
10.

Second messenger signalling governs Escherichia coli biofilm induction upon ribosomal stress.

Boehm A, Steiner S, Zaehringer F, Casanova A, Hamburger F, Ritz D, Keck W, Ackermann M, Schirmer T, Jenal U.

Mol Microbiol. 2009 Jun;72(6):1500-16. doi: 10.1111/j.1365-2958.2009.06739.x. Epub 2009 May 15.

11.

Evaluation of a fall detector based on accelerometers: a pilot study.

Lindemann U, Hock A, Stuber M, Keck W, Becker C.

Med Biol Eng Comput. 2005 Sep;43(5):548-51.

PMID:
16411625
12.

The microbial postgenomic era: promises, problems and prospects.

Gray CP, Keck W.

Expert Opin Investig Drugs. 1998 Feb;7(2):145-8.

PMID:
15991948
13.

Pathogenic bacteria: how to get them back into the line of fire?

Keck W, Hubschwerlen C.

Curr Opin Investig Drugs. 2005 Feb;6(2):139-40. No abstract available.

PMID:
15751735
14.
15.

Peptide deformylase as an antibacterial drug target: target validation and resistance development.

Apfel CM, Locher H, Evers S, Takács B, Hubschwerlen C, Pirson W, Page MG, Keck W.

Antimicrob Agents Chemother. 2001 Apr;45(4):1058-64.

16.

Peptide deformylase as an antibacterial drug target: assays for detection of its inhibition in Escherichia coli cell homogenates and intact cells.

Apfel CM, Evers S, Hubschwerlen C, Pirson W, Page MG, Keck W.

Antimicrob Agents Chemother. 2001 Apr;45(4):1053-7.

17.

Mosaic genes and mosaic chromosomes: intra- and interspecies genomic variation of Streptococcus pneumoniae.

Hakenbeck R, Balmelle N, Weber B, Gardès C, Keck W, de Saizieu A.

Infect Immun. 2001 Apr;69(4):2477-86.

18.

Bacterial targets and antibiotics: genome-based drug discovery.

Gray CP, Keck W.

Cell Mol Life Sci. 1999 Nov 30;56(9-10):779-87. Review.

PMID:
11212338
19.
20.

Microarray-based identification of a novel Streptococcus pneumoniae regulon controlled by an autoinduced peptide.

de Saizieu A, Gardès C, Flint N, Wagner C, Kamber M, Mitchell TJ, Keck W, Amrein KE, Lange R.

J Bacteriol. 2000 Sep;182(17):4696-703.

21.

Crystal structure of Escherichia coli lytic transglycosylase Slt35 reveals a lysozyme-like catalytic domain with an EF-hand.

van Asselt EJ, Dijkstra AJ, Kalk KH, Takacs B, Keck W, Dijkstra BW.

Structure. 1999 Oct 15;7(10):1167-80.

22.

Domain organization and molecular characterization of 13 two-component systems identified by genome sequencing of Streptococcus pneumoniae.

Lange R, Wagner C, de Saizieu A, Flint N, Molnos J, Stieger M, Caspers P, Kamber M, Keck W, Amrein KE.

Gene. 1999 Sep 3;237(1):223-34.

PMID:
10524254
23.

Integrational plasmids for the tetracycline-regulated expression of genes in Streptococcus pneumoniae.

Stieger M, Wohlgensinger B, Kamber M, Lutz R, Keck W.

Gene. 1999 Jan 21;226(2):243-51.

PMID:
9931496
24.
25.

[Modular studying--the new concept of medical technology curriculum of the Ulm Technical University].

Keck W.

Biomed Tech (Berl). 1998;43 Suppl:458-9. German. No abstract available.

PMID:
9859441
26.

Strategies towards a better understanding of antibiotic action: folate pathway inhibition in Haemophilus influenzae as an example.

Evers S, Di Padova K, Meyer M, Fountoulakis M, Keck W, Gray CP.

Electrophoresis. 1998 Aug;19(11):1980-8.

PMID:
9740058
27.

Acquisition of five high-Mr penicillin-binding protein variants during transfer of high-level beta-lactam resistance from Streptococcus mitis to Streptococcus pneumoniae.

Hakenbeck R, König A, Kern I, van der Linden M, Keck W, Billot-Klein D, Legrand R, Schoot B, Gutmann L.

J Bacteriol. 1998 Apr;180(7):1831-40.

28.

[Volumetric and morphological CT parameters for assessing prognosis and treatment control in hepatocellular carcinoma undergoing arterial chemoembolization].

Vogl TJ, Trapp M, Pegios W, Mack M, Bechstein WO, Keck W, Scholz A, Schröder H, Neuhaus P, Felix R.

Rofo. 1997 Sep;167(3):219-26. German.

PMID:
9376548
29.

Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays.

de Saizieu A, Certa U, Warrington J, Gray C, Keck W, Mous J.

Nat Biotechnol. 1998 Jan;16(1):45-8. Review.

PMID:
9447592
30.
31.

Peptidoglycan as a barrier to transenvelope transport.

Dijkstra AJ, Keck W.

J Bacteriol. 1996 Oct;178(19):5555-62. Review. No abstract available.

32.

The monofunctional glycosyltransferase of Escherichia coli is a member of a new class of peptidoglycan-synthesising enzymes.

Di Berardino M, Dijkstra A, Stüber D, Keck W, Gubler M.

FEBS Lett. 1996 Aug 26;392(2):184-8.

33.
34.

Purification and characterization of N-acetylmuramyl-L-alanine amidase from human plasma using monoclonal antibodies.

Hoijer MA, Melief MJ, Keck W, Hazenberg MP.

Biochim Biophys Acta. 1996 Feb 9;1289(1):57-64.

PMID:
8605233
35.
36.
37.

Effect of pyrimido[1,6-a]benzimidazoles, quinolones, and Ca2+ on the DNA gyrase-mediated cleavage reaction.

Gmünder H, Kuratli K, Keck W.

Antimicrob Agents Chemother. 1995 Jan;39(1):163-9.

38.

Site-directed mutagenesis of proposed active-site residues of penicillin-binding protein 5 from Escherichia coli.

van der Linden MP, de Haan L, Dideberg O, Keck W.

Biochem J. 1994 Oct 15;303 ( Pt 2):357-62.

39.
40.

G(AnH)MTetra, a naturally occurring 1,6-anhydro muramyl dipeptide, induces granulocyte colony-stimulating factor expression in human monocytes: a molecular analysis.

Dokter WH, Dijkstra AJ, Koopmans SB, Mulder AB, Stulp BK, Halie MR, Keck W, Vellenga E.

Infect Immun. 1994 Jul;62(7):2953-7.

41.

Doughnut-shaped structure of a bacterial muramidase revealed by X-ray crystallography.

Thunnissen AM, Dijkstra AJ, Kalk KH, Rozeboom HJ, Engel H, Keck W, Dijkstra BW.

Nature. 1994 Feb 24;367(6465):750-3.

PMID:
8107871
42.

Engineering and overexpression of periplasmic forms of the penicillin-binding protein 3 of Escherichia coli.

Fraipont C, Adam M, Nguyen-Distèche M, Keck W, Van Beeumen J, Ayala JA, Granier B, Hara H, Ghuysen JM.

Biochem J. 1994 Feb 15;298 ( Pt 1):189-95.

43.

G(Anh)MTetra, a natural bacterial cell wall breakdown product, induces interleukin-1 beta and interleukin-6 expression in human monocytes. A study of the molecular mechanisms involved in inflammatory cytokine expression.

Dokter WH, Dijkstra AJ, Koopmans SB, Stulp BK, Keck W, Halie MR, Vellenga E.

J Biol Chem. 1994 Feb 11;269(6):4201-6. Erratum in: J Biol Chem 1994 Jun 17;269(24):16983.

44.

Crystallization of a genetically engineered water-soluble primary penicillin target enzyme. The high molecular mass PBP2x of Streptococcus pneumoniae.

Charlier P, Buisson G, Dideberg O, Wierenga J, Keck W, Laible G, Hakenbeck R.

J Mol Biol. 1993 Aug 5;232(3):1007-9.

45.
46.

In vivo crystal formation in Escherichia coli of an over-expressed soluble form of penicillin-binding protein 5.

van der Linden MP, Vonck J, Sjollema KA, Keck W.

FEMS Microbiol Lett. 1992 Dec 1;78(2-3):117-23.

PMID:
1490594
47.

Possible role of Escherichia coli penicillin-binding protein 6 in stabilization of stationary-phase peptidoglycan.

van der Linden MP, de Haan L, Hoyer MA, Keck W.

J Bacteriol. 1992 Dec;174(23):7572-8.

49.

Murein-metabolizing enzymes from Escherichia coli: existence of a second lytic transglycosylase.

Engel H, Smink AJ, van Wijngaarden L, Keck W.

J Bacteriol. 1992 Oct;174(20):6394-403.

50.

Enzymatic preparation of 1,6-anhydro-muropeptides by immobilized murein hydrolases from Escherichia coli fused to staphylococcal protein A.

Engel H, van Leeuwen A, Dijkstra A, Keck W.

Appl Microbiol Biotechnol. 1992 Sep;37(6):772-83.

PMID:
1369491

Supplemental Content

Support Center